MindMed To Begin Clinical Trials On Ayahuasca's Active Ingre Biopharmaceutical and psychedelics research company Mind Medicine Inc. (NEO:MMED) MMEDF 6.59% announced Thursday that it will begin studying DMT’s effects on humans in a Phase 1 clinical trial conducted in collaboration with University Hospital Basel in Switzerland.
Understanding The Effects Of Ayahuasca’s Active Ingredient
DMT, an abbreviation of N,N-Dimethyltryptamine, is the main active ingredient in ayahuasca, a hallucinogenic brew traditionally used as a spiritual medicine in shamanic ceremonies among indigenous communities in South America.
From a clinical perspective, DMT differs from other psychedelic drugs like LSD or psilocybin in its shorter onset and offset action.